Stay updated on Subcutaneous Nivolumab + rHuPH20 Clinical Trial
Sign up to get notified when there's something new on the Subcutaneous Nivolumab + rHuPH20 Clinical Trial page.

Latest updates to the Subcutaneous Nivolumab + rHuPH20 Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedThe Locations section was updated with numerous additions and deletions across sites in the United States, Argentina, Brazil, Chile, France, Italy, Mexico, the Netherlands, New Zealand, Poland, Spain, the United Kingdom, and more (e.g., Georgia, Maryland, Michigan, North Carolina, Oregon, Rio Grande do Sul, Mexico City, North Holland, Bay of Plenty, Masovian Voivodeship, Glamorgan). Revision: v3.3.3 was posted, replacing the previous v3.3.2.SummaryDifference1%

- Check25 days agoNo Change Detected
- Check46 days agoChange DetectedAdded a note that publications are automatically filled from PubMed and may not be about the study. Updated the page revision from v3.2.0 to v3.3.2.SummaryDifference0.1%

- Check54 days agoChange DetectedThe study’s outcome assessment windows and follow-up durations were updated to extend monitoring to up to about 70 months, replacing shorter timeframes. A government funding lapse notice previously shown on the page has been removed.SummaryDifference0.7%

- Check75 days agoChange DetectedResults for the study have been posted on the page, including a 'Results First Posted' date (2025-02-20) and related outcome data added to the study record.SummaryDifference0.3%

- Check90 days agoChange DetectedAdded a new PubMed publication entry (CheckMate 8KX pharmacokinetics/safety study) to the Publications section; no deletions or core-content changes detected.SummaryDifference3%

- Check97 days agoChange DetectedSummary of changes: updated operating status notice and version to v3.2.0, replacing the previous v3.1.0.SummaryDifference3%

Stay in the know with updates to Subcutaneous Nivolumab + rHuPH20 Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Subcutaneous Nivolumab + rHuPH20 Clinical Trial page.